Analyzing 12 years of deidentified patient electronic records using AI, researchers discovered that glucosamine use among individuals with Mild Cognitive Impairment (MCI) is associated with a 25% higher likelihood of progressing to full dementia, alongside a 25% spike in mortality for established Alzheimer’s patients.
